Terlipressin Administration in Septic Shock Refractory to Catecholamines
NCT ID: NCT00793559
Last Updated: 2008-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
30 participants
INTERVENTIONAL
2008-11-30
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the TerliNor Study
NCT03336814
Continuous Infusion of Terlipressin in Septic Shock
NCT00481572
Terlipressin in Septic Shock: Effects on Microcirculation
NCT00995839
Terlipressin for Refractory Septic Shock
NCT04339868
Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.
NCT04819568
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
terlipressin bolus
1 mg of terlipressin received one time only
terlipressin
1 mg of terlipressin one time only
terlipressin drip
terlipressin
1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
terlipressin
1 mg of terlipressin one time only
terlipressin
1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assaf-Harofeh Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Assaf-Harofeh Medical Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tal Mann, Dr
Role: STUDY_DIRECTOR
Asaf Harofeh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asaf Harofeh MC
Zrifin, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
161/08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.